Ocular Therapeutix Inc
OCUL11.920USD
0.0000.00%
收盤 08/01, 16:00（美東）報價延遲15分鐘
1.90B總市值
虧損本益比TTM
關於 Ocular Therapeutix Inc 公司
Ocular Therapeutix, Inc. 是一家生物製藥公司。該公司致力於開發和商業化治療溼性老年性黃斑變性 (wet AMD)、糖尿病視網膜病變和其他眼部疾病和病症的療法。其首款商業化藥物產品 DEXTENZA 用於治療眼科手術後的眼部炎症和疼痛以及與過敏性結膜炎相關的眼部瘙癢。該公司還在開發另外兩種臨牀階段資產，OTX-DED（地塞米松小管內插入物）用於短期治療乾眼症的體徵和症狀，OTX-CSI（環孢菌素小管內插入物）用於長期治療乾眼症。該公司正在進行一項關鍵的 III 期臨牀試驗，以評估 AXPAXLI 對溼性 AMD 的治療效果。其臨牀產品組合還包括 PAXTRAVA，該產品正處於 III 期臨牀開發階段，用於治療原發性開角型青光眼 (OAG) 或眼高壓 (OHT)。
公司簡介
公司代碼OCUL
公司名稱Ocular Therapeutix Inc
上市日期Jul 25, 2014
CEODr. Pravin U. Dugel, M.D.
員工數量274
證券類型Ordinary Share
年結日Jul 25
公司地址15 Crosby Drive
城市BEDFORD
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編01730
電話17813574000
網址https://www.ocutx.com/
公司代碼OCUL
上市日期Jul 25, 2014
CEODr. Pravin U. Dugel, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
3.50M
-0.60%
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
Chief Strategy Officer
281.62K
-0.66%
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Independent Director
174.70K
+8.71%
Mr. Charles M. Warden
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
74.46K
+23.15%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
50.00K
+38.89%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
34.93K
+66.88%
Dr. Seung Suh Hong, Ph.D.
Dr. Seung Suh Hong, Ph.D.
Independent Director
Independent Director
34.93K
+66.88%
Mr. Donald D. Notman, Jr.
Mr. Donald D. Notman, Jr.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Ms. Leslie J. Williams
Ms. Leslie J. Williams
Independent Director
Independent Director
--
--
Mr. Todd D.C. Anderman
Mr. Todd D.C. Anderman
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
3.50M
-0.60%
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
Chief Strategy Officer
281.62K
-0.66%
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Independent Director
174.70K
+8.71%
Mr. Charles M. Warden
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
74.46K
+23.15%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
50.00K
+38.89%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
34.93K
+66.88%
收入明細
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
63.72M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月20日 週二
更新時間: 5月20日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Deep Track Capital LP
8.97%
Summer Road, LLC
8.71%
VR Adviser, LLC
8.01%
BlackRock Institutional Trust Company, N.A.
6.79%
The Vanguard Group, Inc.
5.24%
Other
62.28%
持股股東
持股股東
佔比
Deep Track Capital LP
8.97%
Summer Road, LLC
8.71%
VR Adviser, LLC
8.01%
BlackRock Institutional Trust Company, N.A.
6.79%
The Vanguard Group, Inc.
5.24%
Other
62.28%
股東類型
持股股東
佔比
Investment Advisor
24.44%
Investment Advisor/Hedge Fund
24.34%
Hedge Fund
24.14%
Venture Capital
9.47%
Individual Investor
3.87%
Research Firm
2.70%
Private Equity
1.43%
Pension Fund
0.35%
Bank and Trust
0.31%
Other
8.95%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
380
145.26M
91.19%
-6.08M
2025Q1
391
145.03M
91.13%
-3.83M
2024Q4
382
137.38M
86.40%
-14.17M
2024Q3
370
142.63M
91.08%
-5.76M
2024Q2
356
140.04M
90.02%
+6.94M
2024Q1
335
125.94M
81.55%
+41.06M
2023Q4
313
75.41M
65.72%
+26.62M
2023Q3
319
44.73M
56.36%
-8.88M
2023Q2
327
47.63M
60.14%
-3.66M
2023Q1
334
44.52M
57.43%
-7.38M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Deep Track Capital LP
14.29M
8.97%
+1.46M
+11.36%
Mar 31, 2025
Summer Road, LLC
13.88M
8.71%
+8.55K
+0.06%
Mar 31, 2025
VR Adviser, LLC
12.76M
8.01%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.81M
6.79%
+94.61K
+0.88%
Mar 31, 2025
The Vanguard Group, Inc.
8.34M
5.24%
-119.40K
-1.41%
Mar 31, 2025
Avoro Capital Advisors LLC
8.06M
5.06%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
5.32M
3.34%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
5.20M
3.26%
+1.60M
+44.44%
Mar 31, 2025
Citadel Advisors LLC
4.81M
3.02%
+354.30K
+7.95%
Mar 31, 2025
Dugel (Pravin U)
3.50M
2.2%
-21.22K
-0.60%
May 23, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Pharmaceuticals ETF
3.62%
SPDR S&P Pharmaceuticals ETF
2.01%
Invesco Dorsey Wright Healthcare Momentum ETF
1.94%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.42%
iShares U.S. Pharmaceuticals ETF
0.6%
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
Invesco Nasdaq Biotechnology ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Russell 2000 Growth ETF
0.09%
Proshares Ultra Russell 2000
0.05%
查看更多
Invesco Pharmaceuticals ETF
佔比3.62%
SPDR S&P Pharmaceuticals ETF
佔比2.01%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.94%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.42%
iShares U.S. Pharmaceuticals ETF
佔比0.6%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.42%
Invesco Nasdaq Biotechnology ETF
佔比0.16%
ProShares Ultra Nasdaq Biotechnology
佔比0.16%
iShares Russell 2000 Growth ETF
佔比0.09%
Proshares Ultra Russell 2000
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
